Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

S

Sarfez Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Body Weight Changes

Treatments

Drug: CHF Patients: Furosemide 40 mg
Drug: CHF Patients: ER Torsemide 40 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT03509545
CLCD-075-17

Details and patient eligibility

About

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Full description

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Enrollment

20 patients

Sex

Male

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion criteria

  • Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

20 participants in 2 patient groups

CHF Patients: ER Torsemide 40 mg
Experimental group
Description:
CHF patients will be given 40 mg ER Torsemide
Treatment:
Drug: CHF Patients: ER Torsemide 40 mg
CHF Patients: Furosemide 40 mg
Active Comparator group
Description:
CHF patients are on 40 mg of Furosemide
Treatment:
Drug: CHF Patients: Furosemide 40 mg

Trial contacts and locations

1

Loading...

Central trial contact

Jaya Patel, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems